Summary
Cisplatin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Thyroid Cancer (Well-Differentiated) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Thyroid Cancer (Well-Differentiated). ClinicalTrials.gov lists 8 registered trials linking Cisplatin to Thyroid Cancer (Well-Differentiated): 2 are active or not yet recruiting; 5 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT01057589). The largest enrolment is 200 participants (NCT04521686). Registration activity spans 1994 to 2024. No published literature item is linked to Cisplatin and Thyroid Cancer (Well-Differentiated) in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Thyroid Cancer ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Not applicable — surgical resection is standard; papillary microcarcinoma (<1 cm, low-risk): active surveillance achieves 99.8%+ cancer-specific survival at 10 years without immediate surgery in Japanese cohorts.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 43.0 (trials 23.0, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 0 recruiting, 2 active / not yet recruiting, 5 completed, 1 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | EGFR |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT00002608 | Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors 1994 | completed | Phase 2 | 30 |
| NCT01057589 | A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer 2010 | completed | Phase 2 | 66 |
| NCT00021333 | Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer 1999 | completed | Phase 2 | 29 |
| NCT06713057 | Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer 2024 | not yet recruiting | Phase 2 | 20 |
| NCT04521686 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations 2020 | active, not recruiting | Phase 1 | 200 |
| NCT00405405 | Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer 2006 | completed | Phase 1 | 13 |
| NCT01240590 | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) 2011 | completed | PHASE1, PHASE2 | 27 |
| NCT00077103 | Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer 2003 | terminated | PHASE1, PHASE2 | 4 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target EGFR. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Cisplatin approved for Thyroid Cancer (Well-Differentiated)?
Cisplatin has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Thyroid Cancer (Well-Differentiated) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Thyroid Cancer (Well-Differentiated). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Cisplatin in clinical trials for Thyroid Cancer (Well-Differentiated)?
ClinicalTrials.gov lists 8 registered trials linking Cisplatin to Thyroid Cancer (Well-Differentiated): 2 are active or not yet recruiting; 5 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT01057589). The largest enrolment is 200 participants (NCT04521686). Registration activity spans 1994 to 2024.
What does the evidence show for Cisplatin in Thyroid Cancer (Well-Differentiated)?
Cisplatin has 5 completed registered trials for Thyroid Cancer (Well-Differentiated) but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target EGFR. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.